About the Role:
We are seeking an exceptional individual with industry experience in antibody development for a Senior Platform Scientist role to lead the development of in single chain antibody fragments (scFvs) on Protillion’s high-throughput protein engineering platform via novel in vitro translation methods.
The role will require subject matter expertise and scientific leadership. The successful candidate will have the ability to both be an exceptional individual contributor as well as a team leader as the organization continues to expand.
Job Responsibilities:
- Primary responsibility for the development and optimization of high-throughput in vitro transcription and translation methods for antibodies and antibody fragments
- Primary responsibility for the development and optimization of scFv expression and folding, specifically, using prokaryotic cell-free expression systems
- Sourcing and optimization of various cell-free protein synthesis systems
Requirements:
- Ph.D. in molecular biology, structural biology, immunology or related field with at least 3 years of experience in an antibody development environment.
- Deep understanding of the principles of various IVTT methods especially as they may apply towards production of antibodies and antibody fragments.
- Intimate knowledge of cell-free protein synthesis systems (commercially available products, providers and their limitations), as well as experience in developing such systems
- Experience with the development of one or more protein display technologies (such as ribosome display)
- A documented understanding of the principles of antibody stability, solubility, as well as industry standard methods, and computational approaches for the evaluation of the above.
Also a plus:
- Experience working at an early-stage startup environment
- Passion for improving lives through biotechnology innovation
Compensation Range: $90,000/yr - $165,000/yr
Top Skills
What We Do
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.
